Cytokinetics’ muscle gambit nears POC for next-gen therapies

How Cytokinetics' muscle biology decision may bear fruit in next-gen therapies

Cytokinetics is banking that its nearly 15 years of muscle biology research will pay dividends with its next-generation therapies for cardiovascular and neuromuscular disorders. The next signal will come in early May when the biotech reports Phase II data for reldesemtiv in ALS.

Over its 21 year history -- the first six of which were spent in cancer -- Cytokinetics Inc. has seen its share of wins and losses.

While many of its peers were flocking into oncology, Cytokinetics went in the opposite direction, entering a field with relatively few competitors, but equally sparse understanding of the translational biology.

“There really aren’t any other companies focused on muscle and how to augment muscle performance in ways that are therapeutically gainful,” said President and CEO Robert Blum. “We embarked on that path knowing it was going to

Read the full 1362 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE